Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out

MEBO - UBIOME study 2018

MEBO Gut Microbiome Study
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person

Participation info : LINK English

MEBO Private Facebook Group
to join : go to
or contact
Ubiome Gut EXPLORER : 10% OFF
Join/Watch the weekly
TMAU UP Podcasts

Videos : TMAU stories

MEBO Map Testing & Meetups

Full details :
want listed ? contact
Metabolomic Profiling Study

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned

Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
NORD Member Organization
See RareConnect

£ 943.03/GBP
$ 568.00/USD

TOTAL at today's ROE
£0.80/GBP = $1.00/USD

£1,398.07 = $1,745.14



Your currency will be automatically converted to USD or GBP by PayPal.

Option: pay with your credit card instead of PayPal account by clicking on either Donate button above.

Popular Posts (last 30 days)

Upcoming get-togethers

Let us know if you want a meetup listed

Subscribe to Blog

Enter your email address:

Delivered by FeedBurner

You will be sent a verification email

Subscribe in a reader

Blog Archive

Wednesday, August 6, 2008

Paper: Transient trimethylaminuria in childhood, not because of poor enzyme function : 1998 Paper

This 1998 paper reports on two unrelated and otherwise healthy children with transient trimethylaminuria, a hitherto unknown abnormality, without N-oxidation deficiency. This demonstrates that a diagnosis of fish-odour syndrome should include the analysis of urinary excretion not only of trimethylamine but also of trimethylamine-N-oxide (TMAO).
Mayatepek E, Kohlmüller D
Children's Hospital, Heidelberg, Germany

Comment from the author who is a sufferer, not an expert:

There are 2 points of interest regarding this study. One is that it is now suggested that FMO1 is the most common form of the FMO enzyme in the human fetus. FMO3 then starts to express itself after birth, but can take quite a few years to fully develop. Around 9 or even teen years has been mentioned. FMO3 is the dominant FMO enzyme in humans after birth.

The other is that the paper suggests tma-n-oxide should be tested. Perhaps up until then, only tma levels were checked. Now 'primary TMAU' diagnosis seems to be based upon the levels of tma-n-oxide a person produces, since this is the correct finished metabolite. It may also explain why in the UK, they accept a diagnosis of 'Secondary TMAU', where the result is given because of too much TMA in the urine. In the case of the paper, today that would be regarded as Secondary TMAU cases (i.e. too much trimethylamine).


Post a Comment